CONTACT US
White Papers

The CardioCare Platform Addresses Real-World Challenges in Structural Heart Disease Patient Care

Share on social: 

LinkedIn
Twitter
Facebook

Follow egnite on social:

Linkedin Twitter Youtube

Related Articles
Press

egnite Introduces Customer Access to Its National Cardiovascular Registry and Launches 2026 Call for Science Investigator-Initiated Study Program

egnite, Inc., a leading digital health company specializing in cardiovascular care, today announced the addition of two distinguished physicians, Vinod H. Thourani, MD and Nicholas Amoroso, MD to its Medical Advisory Board. Their wealth of expertise in cardiovascular care and dedication to innovation will significantly contribute to egnite’s mission to improve cardiovascular patient care nationwide.
egnite Research

Cath Lab Capacity is Up—But Structural Heart Procedures Are Being Outpaced by Other Interventions

Heart failure with a preserved ejection fraction (HFpEF) accounts for more than half of all heart failure cases and carries significant morbidity and mortality risk, especially after hospitalization1. Historically, management of the disease is largely focused on comorbidity management and lifestyle modifications, given that available therapies had not demonstrated sufficient impact on hospitalization burden or mortality. In recent years, however, the treatment paradigm for HFpEF has shifted, with a growing emphasis on SGLT2 inhibitors (SGLT2i). Originally developed to lower blood glucose levels in diabetic patients, several clinical trials have firmly established that SGLT2i is also beneficial for patients living with HFpEF2.
egnite Research

From Black Box to Breakthrough: Unlocking Hidden Care Patterns with LLM-Enriched Data

Heart failure with a preserved ejection fraction (HFpEF) accounts for more than half of all heart failure cases and carries significant morbidity and mortality risk, especially after hospitalization1. Historically, management of the disease is largely focused on comorbidity management and lifestyle modifications, given that available therapies had not demonstrated sufficient impact on hospitalization burden or mortality. In recent years, however, the treatment paradigm for HFpEF has shifted, with a growing emphasis on SGLT2 inhibitors (SGLT2i). Originally developed to lower blood glucose levels in diabetic patients, several clinical trials have firmly established that SGLT2i is also beneficial for patients living with HFpEF2.